{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ04802",
      "entity_text" : "incretin",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:4369359",
      "entity_text" : "Sitagliptin",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Sitagliptin is a dipeptidyl peptidase-4 inhibitor that is used to treat diabetes [XREF_BIBR, XREF_BIBR], especially patients with type 2 diabetes and reduced incretin activity [XREF_BIBR, XREF_BIBR].",
  "reading_complete" : "2020-08-02T16:13:26Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T16:12:32Z",
  "trigger" : "reduced",
  "evidence" : [ "Sitagliptin is a dipeptidyl peptidase-4 inhibitor that is used to treat diabetes [ XREF_BIBR ,  XREF_BIBR ], especially patients with type 2 diabetes and reduced incretin" ],
  "pmc_id" : "3651072",
  "score" : 0
}